Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma

Krisztina Mita Gabor, Z. Sápi, Lilla Gyorgyi Tiszlavicz, Anita Fige, C. Bereczki, Katalin Bartyik

Research output: Article

9 Citations (Scopus)

Abstract

Pseudomyogenic hemangioendothelioma (PMH) is a rare, mostly indolent vascular tumor. Extensive cases are treated with amputation as chemotherapy seems to be ineffective. Recently, promising results were published using mammalian target of rapamycin (mTOR) inhibitors in tumors of vascular origin. Here, we present a case of a child with advanced PMH relapsing after surgery and chemotherapy. Sirolimus achieved significant clinical improvement and stabilization of the lesions without any remarkable toxicity. This case contributes to the growing evidence regarding the efficacy of mTOR inhibitors, such as sirolimus, in multifocal PMH.

Original languageEnglish
Article numbere26781
JournalPediatric Blood and Cancer
Volume65
Issue number2
DOIs
Publication statusPublished - febr. 1 2018

Fingerprint

Hemangioendothelioma
Sirolimus
Blood Vessels
Drug Therapy
Therapeutics
Amputation
Neoplasms

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. / Gabor, Krisztina Mita; Sápi, Z.; Tiszlavicz, Lilla Gyorgyi; Fige, Anita; Bereczki, C.; Bartyik, Katalin.

In: Pediatric Blood and Cancer, Vol. 65, No. 2, e26781, 01.02.2018.

Research output: Article

Gabor, Krisztina Mita ; Sápi, Z. ; Tiszlavicz, Lilla Gyorgyi ; Fige, Anita ; Bereczki, C. ; Bartyik, Katalin. / Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. In: Pediatric Blood and Cancer. 2018 ; Vol. 65, No. 2.
@article{fc31a2b32af744ad9aaed7ae282ce059,
title = "Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma",
abstract = "Pseudomyogenic hemangioendothelioma (PMH) is a rare, mostly indolent vascular tumor. Extensive cases are treated with amputation as chemotherapy seems to be ineffective. Recently, promising results were published using mammalian target of rapamycin (mTOR) inhibitors in tumors of vascular origin. Here, we present a case of a child with advanced PMH relapsing after surgery and chemotherapy. Sirolimus achieved significant clinical improvement and stabilization of the lesions without any remarkable toxicity. This case contributes to the growing evidence regarding the efficacy of mTOR inhibitors, such as sirolimus, in multifocal PMH.",
keywords = "mTOR inhibition, pseudomyogenic hemangioendothelioma, sirolimus",
author = "Gabor, {Krisztina Mita} and Z. S{\'a}pi and Tiszlavicz, {Lilla Gyorgyi} and Anita Fige and C. Bereczki and Katalin Bartyik",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/pbc.26781",
language = "English",
volume = "65",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma

AU - Gabor, Krisztina Mita

AU - Sápi, Z.

AU - Tiszlavicz, Lilla Gyorgyi

AU - Fige, Anita

AU - Bereczki, C.

AU - Bartyik, Katalin

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Pseudomyogenic hemangioendothelioma (PMH) is a rare, mostly indolent vascular tumor. Extensive cases are treated with amputation as chemotherapy seems to be ineffective. Recently, promising results were published using mammalian target of rapamycin (mTOR) inhibitors in tumors of vascular origin. Here, we present a case of a child with advanced PMH relapsing after surgery and chemotherapy. Sirolimus achieved significant clinical improvement and stabilization of the lesions without any remarkable toxicity. This case contributes to the growing evidence regarding the efficacy of mTOR inhibitors, such as sirolimus, in multifocal PMH.

AB - Pseudomyogenic hemangioendothelioma (PMH) is a rare, mostly indolent vascular tumor. Extensive cases are treated with amputation as chemotherapy seems to be ineffective. Recently, promising results were published using mammalian target of rapamycin (mTOR) inhibitors in tumors of vascular origin. Here, we present a case of a child with advanced PMH relapsing after surgery and chemotherapy. Sirolimus achieved significant clinical improvement and stabilization of the lesions without any remarkable toxicity. This case contributes to the growing evidence regarding the efficacy of mTOR inhibitors, such as sirolimus, in multifocal PMH.

KW - mTOR inhibition

KW - pseudomyogenic hemangioendothelioma

KW - sirolimus

UR - http://www.scopus.com/inward/record.url?scp=85038589473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038589473&partnerID=8YFLogxK

U2 - 10.1002/pbc.26781

DO - 10.1002/pbc.26781

M3 - Article

C2 - 28843050

AN - SCOPUS:85038589473

VL - 65

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

M1 - e26781

ER -